Development of a sensitive and selective assay for the determination of procarboxypeptidase U (thrombin-activatable fibrinolysis inhibitor) in plasma

被引:19
作者
Heylen, Evelien [1 ]
Van Goethem, Sebastiaan [2 ]
Willemse, Johan [1 ]
Olsson, Thomas [3 ]
Augustyns, Koen [2 ]
Hendriks, Dirk [1 ]
机构
[1] Univ Antwerp, Med Biochem Lab, B-2610 Antwerp, Belgium
[2] Univ Antwerp, Med Chem Lab, B-2610 Antwerp, Belgium
[3] AstraZeneco R&D, SE-43183 Molndal, Sweden
关键词
TAFIA; THRESHOLD; RISK;
D O I
10.1016/j.ab.2009.08.037
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
To date, several assays for procarboxypeptidase U (proCPU) determination exist, all having their own inherent disadvantages and advantages. A drawback of activity-based assays is the interference of the constitutively active carboxypeptidase N (CPN) in plasma. Recent screening of Bz-Xaa-Arg peptides with modified aromatic amino acids at the P1 position revealed a selective CPU substrate, N-benzoyl-ortho-cyano-phenylalanyl-arginine (Bz-o-cyano-Phe-Arg), which will allow straightforward determination of proCPU in plasma. Our assay shows an excellent linearity in the concentration range of 20-2600 U/L, with within- and between-run precision values of 2.7% and 4.6%, respectively. A good correlation with our high-performance liquid chromatography (HPLC)-assisted proCPU activity assay using hippuryl-L-arginine (HipArg) as substrate was found. Besides the major improvement regarding the selectivity, the assay is much easier to perform and far less time-consuming compared with the proCPU activity assay using HipArg as substrate. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:152 / 154
页数:3
相关论文
共 17 条
  • [1] PURIFICATION AND CHARACTERIZATION OF TAFI, A THROMBIN-ACTIVABLE FIBRINOLYSIS INHIBITOR
    BAJZAR, L
    MANUEL, R
    NESHEIM, ME
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (24) : 14477 - 14484
  • [2] STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT
    BLAND, JM
    ALTMAN, DG
    [J]. LANCET, 1986, 1 (8476) : 307 - 310
  • [3] Curiouser and curiouser: Recent advances in measurement of thrombin-activatable fibirinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles
    Boffa, Michael B.
    Koschinsky, Marlys L.
    [J]. CLINICAL BIOCHEMISTRY, 2007, 40 (07) : 431 - 442
  • [4] Carboxypeptidase U (TAFIa) decreases the efficacy of thrombolytic therapy in ischemic stroke patients
    Brouns, Raf
    Heylen, Evelien
    Sheorajpanday, Rishi
    Willemse, Johan L.
    Kunnen, Jan
    De Surgeloose, Didier
    Hendriks, Dirk F.
    De Deyn, Peter P.
    [J]. CLINICAL NEUROLOGY AND NEUROSURGERY, 2009, 111 (02) : 165 - 170
  • [5] Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism
    Eichinger, S
    Schönauer, V
    Weltermann, A
    Minar, E
    Bialonczyk, C
    Hirschl, M
    Schneider, B
    Quehenberger, P
    Kyrle, PA
    [J]. BLOOD, 2004, 103 (10) : 3773 - 3776
  • [6] HENDRIKS D, 1989, CLIN CHEM, V35, P177
  • [7] Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia
    Heylen, Evelien
    Miljic, Predrag
    Willemse, Johan
    Djordjevic, Valentina
    Radojkovic, Dragica
    Colovic, Milica
    Elezovic, Ivo
    Hendriks, Dirk
    [J]. THROMBOSIS RESEARCH, 2009, 124 (04) : 427 - 432
  • [8] Carboxypeptidase U (TAFIa) prevents lysis from proceeding into the propagation phase through a threshold-dependent mechanism
    Leurs, J
    Nerme, V
    Sim, Y
    Hendriks, D
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (03) : 416 - 423
  • [9] Schatteman KA, 1999, CLIN CHEM, V45, P807
  • [10] Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis
    van Tilburg, NH
    Rosendaal, FR
    Bertina, RM
    [J]. BLOOD, 2000, 95 (09) : 2855 - 2859